Volume 7, Issue 1 pp. 153-154
Letter
Open Access

Gut microbiome alterations in anti-NMDA receptor encephalitis: caveats for result interpretation

Giulia Berzero

Giulia Berzero

AP-HP, Groupe Hospitalier Pitié-Salpêtrière, service de Neurologie 2-Mazarin, Paris, France

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France

PhD program in Biomedical Sciences, University of Pavia, Pavia, Italy

Neuroncology Unit, IRCCS Mondino Foundation, Pavia, Italy

Search for more papers by this author
Dimitri Psimaras

Dimitri Psimaras

AP-HP, Groupe Hospitalier Pitié-Salpêtrière, service de Neurologie 2-Mazarin, Paris, France

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France

Centre de Compétence des Syndromes Neurologiques Paraneoplasiques et Encéphalites Autoimmunes, Groupe Hospitalier Pitié-Salpêtrière, Paris, France

Search for more papers by this author
Nicolas Weiss

Nicolas Weiss

Sorbonne Université, Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN), Assistance Publique - Hôpitaux de Paris, AP-HP.Sorbonne Université, Hôpital Pitié-Salpêtrière, Département de Neurologie, Unité de médecine intensive réanimation neurologique, Paris, France

Search for more papers by this author
Harry Sokol

Harry Sokol

Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Hôpital Saint Antoine, Service de Gastroenterologie, F-75012 Paris, France

INRA, UMR1319 Micalis, AgroParisTech, Jouy-en-Josas, France

Search for more papers by this author
Agusti Alentorn

Corresponding Author

Agusti Alentorn

AP-HP, Groupe Hospitalier Pitié-Salpêtrière, service de Neurologie 2-Mazarin, Paris, France

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France

Correspondence

Agusti Alentorn, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, service de Neurologie 2-Mazarin, 47, Boulevard de l’Hopital, 75013 Paris, France. Tel: +33 (0)14 216 4160; Fax: +33 14 216 0375; E-mail: [email protected]

Search for more papers by this author
First published: 27 December 2019
Citations: 1

Dear Editor,

We read with interest the article published by Gong and colleagues on gut microbiome alterations in patients with anti-N-methyl-D-aspartate (NMDAr) encephalitis.1 The authors deserve credit for conducting a microbiome study in such a difficult population. However, in our view, their results warrant some caveats for interpretation.

The authors found that the gut microbiome of patients with anti-NMDAr encephalitis had higher species richness (i.e., increased alpha diversity) compared to healthy controls. This finding was surprising considering that higher species richness is generally considered beneficial for health.2 A large meta-analysis has recently questioned the reliability of alpha diversity as a marker of dysbiosis in patients with extra-intestinal conditions: associations between alpha diversity and disease that were significant in individual studies proved inconsistent across studies, suggesting that single studies can be plagued by confounding factors and batch effects.3

As microbiome studies are easily affected by confounders, a rigorous methodology is needed to avoid biases.4 In the study by Gong and colleagues, the control group was properly matched for the main factors that are known to affect microbiome composition, such as age, body mass index, and diet. However, no information was provided on the measures undertaken to control other confounding factors that are inherent to study design. The authors do not state whether patients with acute anti-NMDAr encephalitis were receiving corticosteroids or other immune therapies, needed intensive encephalitis were receiving corticosteroids or other immune therapies, needed intensive care resources,5, 6 especially mechanical ventilation7 and do not report for possible antimicrobial agents as this is frequently the case in the ICU setting. Indeed, instead of univariate analysis, a multivariate approach would allow to, at least partially, correct for these cofounding factors.12

Disease-specific microbiome alterations should be distinguished from the nonspecific alterations found across different disorders that represent a generic consequence of bad health.3 This distinction is essential to identify biologically relevant alterations and elaborate appropriate interventions for the disease under consideration.3, 8 Although this analysis was not performed by Gong and colleagues, we believe it could enrich future studies.

Ethnicity, geographical location and diet are important factors to consider in the view of potential clinical applications, as these variables have a strong impact on microbiome composition.9-12 Readers should be aware that the results of the study by Gong and colleagues might not be transferable to western patients due to the substantial differences in ethnic composition, geographical milieu, and dietary intake between the two populations.

Conflict of Interest

The authors have no conflict of interest to disclose.

    The full text of this article hosted at iucr.org is unavailable due to technical difficulties.